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Background: Endometrial cancer is the most common gynecologic malignancy in developed countries. Trop-2 is a
glycoprotein involved in cellular signal transduction and is differentially overexpressed relative to normal tissue in a
variety of human adenocarcinomas, including endometrioid endometrial carcinomas (EEC). Trop-2 overexpression
has been proposed as a marker for biologically aggressive tumor phenotypes.
Methods: Trop-2 protein expression was quantified using tissue microarrays consisting of formalin-fixed paraffin-
embedded specimens from 118 patients who underwent surgical staging from 2001–9 by laparotomy for EEC.
Clinicopathologic characteristics including age, stage, grade, lymphovascular space invasion, and medical
comorbidities were correlated with immunostaining score. Univariate and multivariate analyses were performed for
overall survival, disease-free survival, and progression-free survival in relation to clinical parameters and Trop-2
protein expression.
Results: Clinical outcome data were available for 103 patients. Strong Trop-2 immunostaining was significantly
associated with higher tumor grade (p=0.02) and cervical involvement (p<0.01). Univariate analyses showed a
significant association with reduced disease-free survival (DFS) (p=0.01), and a trend towards significance for overall
and progression-free survival (p=0.06 and p=0.05, respectively). Multivariate analyses revealed Trop-2 overexpression
and advanced FIGO stage to be independent prognostic factors for poor DFS (p=0.04 and p <0.001, respectively).
Conclusions: Trop-2 protein overexpression is significantly associated with higher tumor grade and serves as an
independent prognostic factor for DFS in endometrioid endometrial cancer.
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Endometrial cancer is the most common gynecologic
malignancy in developed countries, with 47,130 new
cases and 8,010 deaths projected for the United States
alone in 2012 [1]. Endometrial carcinomas may be broadly
dichotomized into two classes with distinct underlying
molecular pathogenesis, clinical behavior, and histopath-
ology [2]. Type I endometrial cancers comprise 80% of
cases and are associated with a history of exposure to* Correspondence: bignottieliana@yahoo.it
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reproduction in any medium, provided the orunopposed estrogen, favorable prognosis, and endome-
trioid histology (grade 1 or 2) [3,4]; mutations in k-Ras,
PTEN, or mismatch repair mechanisms predominate
[5,6]. Type II endometrial cancers constitute the minority
of cases, but are typified by an aggressive clinical course
with a distinct pattern of metastasis, older age at presen-
tation, the absence of antecedent history of unopposed
estrogen, and serous, clear cell or grade 3 endometrioid
histology [7,8]; aneuploidy, mutations in p53, and Her2/
Neu overexpression are common [9-12].
Trop-2 (also known as GA733-1, M1S1, EGP-1) is
35kDa transmembrane glycoprotein, encoded by the gene
TACSTD2 of chromosome 1p32. Trop-2 was originallyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to be upregulated in a variety of human carcinomas
[14-20]. Importantly, overexpression relative to normal
tissue has been documented in ovarian, endometrial, and
cervical cancers across a broad range of histologies in-
cluding papillary serous [21-23] and endometrioid [24]
adenocarcinomas, squamous cell carcinomas [25] and
carcinosarcomas [26].
In the era of personalized molecular medicine, the
role of intrinsic tumor biology is increasingly recognized
as a major determinant in clinical course [27]. There is
growing evidence that Trop-2 overexpression portends
adverse oncologic outcome [28-31]. This group has pre-
viously shown that strong expression as assessed by
immunohistochemistry in epithelial ovarian cancers serves
as an independent prognostic factor for decreased overall
survival [32]. Recently, our group has also demonstrated
that Trop-2 expression is significantly higher in endome-
trioid endometrial carcinomas (EEC) compared to nor-
mal tissues representing both proliferative and secretory
phase endometrium, and that strength of immunohis-
tochemistry staining correlates with increasing grade.
Furthermore, compared to those that lack expression,
EEC cell lines that overexpress Trop-2 are highly suscep-
tible to antibody-dependent cellular cytotoxicity medi-
ated by hRS7, a humanized monoclonal antibody against
Trop-2 [24].
In this study, we perform secondary analyses of a sub-
population from our previous work. We describe for the
first time the clinicopathologic significance of Trop-2
overexpression in EEC using a large number of speci-
mens via tissue microarrays (TMAs). This investigation
holds important implications for patient care, under-
standing the contribution of Trop-2 to cancer pathogen-
esis, and further definition of the potential applications
for therapy using hRS7 in the setting of treatment-
refractory disease.Methods
Endometrial carcinoma patients
The tumor tissue samples included in this investigation
were derived from 118 patients sequentially treated at
the Division of Gynecologic Oncology, University of
Brescia, Italy between 2001 and 2009. The study has been
performed following the Declaration of Helsinki set of
principles and it has been approved by the Research Re-
view Board- the Ethic Committee- of the Spedali Civili,
Brescia, Italy (study reference number: 527/B4/4).
The inclusion criteria for the patients were the fol-
lowing: i) diagnosis of endometrial adenocarcinoma,
endometrioid in histology, ii) informed consent obtained
from the patient and iii) sufficient amount of tumor tis-
sue in the FFPE block to create the TMA. All pathologyspecimens were reviewed in our institution and histo-
logical classification was performed according to WHO
criteria, while pathological stage was determined in ac-
cordance with guidelines of the International Federation
of Gynecologists and Obstetricians (FIGO). Tumor tis-
sues were obtained from women undergoing total ab-
dominal hysterectomy, bilateral salpingo-oophorectomy
and peritoneal washings. Lymph node sampling or dis-
section was predominantly performed in patients with
tumors characterized by deep myometrial invasion and/or
high grade or aggressive histology. Obesity and advanced
age were relative contraindications to full surgical staging.
None of the patients had received preoperative chemo-
therapy or radiation. Age, stage, grade, medical comorbid-
ities (e.g., diabetes, obesity, hypertension) and treatment
information were recorded in all cases. A total of 103
patients had sufficient follow-up for inclusion in survival
analyses.Tissue microarrays and immunohistochemistry
TMAs were created from 118 formalin-fixed, paraffin-
embedded EEC tissues collected from the Department of
Surgical Pathology, University of Brescia, Italy. TMAs
were built using an automated tissue microarrayer (TMA
Master, 3DHistech, Budapest, Hungary). Representative
areas were chosen for sampling from haematoxylin and
eosin (H&E) stained sections of selected normal endo-
metrium (NE) and EEC cases. Four 0.6-mm cores were
collected from different areas of each tumor block in
order to overcome sample heterogeneity and the possible
loss of tissue due to cutting. Separate TMAs were created
for low and advanced tumor grade; normal tissue was
included in all TMAs as an internal negative control.
Four micron sections were cut from TMAs and H&E
staining was used for confirmation of tumor tissue. TMA
sections were subjected to antigen retrieval (40 min in
water bath at 98°C in EDTA buffer pH 8.0) before appli-
cation of the purified goat polyclonal antibody against
the recombinant human Trop-2 extracellular domain
(R&D Systems, Inc., Minneapolis, MN) diluted 1:100. The
antibody was revealed with a biotinylated rabbit anti-goat
(Vector Labs, Burlingame, CA), diluted 1:250, followed
by HRP-streptavidin (Dako, Glostrup, Denmark) and dia-
minobenzidine (DAB) as chromogen; hematoxylin was
used for counterstaining.
In the present investigation we used the immunohisto-
chemical scoring method previously published by us in
epithelial ovarian cancer [32]. Briefly, immunoreactivity
was evaluated by three independent observers; membrane
staining was graded for intensity (0-negative, 1-weak,
2-moderate, and 3-strong) and the percentage of posi-
tive cells was scored as 0 (0%), 1 (1-10%), 2 (11-50%),
3 (51-100%). A single immunohistochemistry (IHC) scale
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and the percentage staining score and a total score was
calculated grouping score 0 in total score 0, 1–3 in total
score 1, 4 and 6 in total score 2 and 9 in total score 3.
Digital images were resized by using Adobe Photoshop
(Adobe Systems, Inc., San Jose, CA).
Statistical analysis
The association between Trop-2 immunohistochemical
staining, coded as 0, 1, 2 and 3, and clinical covariates
were evaluated by non-parametric one-way ANOVA and
Wilcoxon-Mann–Whitney tests. For survival analysis,
three endpoints (cancer relapse, cancer progression, and
death due to cancer) were used to calculate disease-free
survival (DFS), progression-free survival (PFS) and over-
all survival (OS), respectively. DFS was defined as the
time interval between the date of surgery and the date of
identification of disease recurrence, PFS was defined as
the time interval between the date of surgery and the
date of identification of progressive disease (disease not
treatable with curative intent) and OS was defined as the
time interval between the date of surgery and the date of
death. For all three endpoints the last date of follow-up
was used for censored subjects. Survival models were fit-
ted using the Cox proportional hazard models, while
survival curves were drawn based on the Kaplan-Meier
methods. The association of Trop-2 immunostaining with
prognosis was evaluated. In all analyses, a p value < 0.05
was considered significant. All the analyses were per-
formed using R (R Development Core Team, 2012) [33].
Results
Trop-2 immunostaining and clinicopathologic variables
The relationship between Trop-2 immunostaining and the
clinical and pathologic features of the 118 endometrial
carcinoma patients is shown in Table 1. Strong Trop-2
immunostaining was significantly associated with higher
tumor grade (p=0.02), consistent with our previous
results [24]. Moreover, Trop-2 protein overexpression
was also significantly correlated with cervical involve-
ment (p<0.01), and, marginally, with deeper myometrial
invasion (p=0.08).
As previously reported by us, negative controls con-
sisting in normal endometrial tissues demonstrated
predominantly a weak immunoreactivity for Trop-2 (see
Bignotti et al. 2011 [24] for figures representing Trop-2
immunostaining).
Trop-2 immunostaining and patient survival
The median follow-up interval was 48.7 months (range
6.1 – 124.9 months). At the time of the last follow up,
86 patients (83.5%) were alive without evidence of disease,
1 patient (1%) was alive with disease, and 16 patients
(15.5%) were dead of disease. The sites of recurrencewere either local (pelvic lymph nodes, vaginal cupola), or
distant (para-aortic lymph nodes, lung, brain, bone).
As expected, known EEC clinical prognostic factors,
such as FIGO stage and lymph node involvement,
showed a statistically significant association with OS, PFS
and DFS in univariate analysis (all p<0.01, Table 2). As
displayed in Figure 1A and in Table 2, stronger Trop-2
immunostaining (IHC score 3 versus IHC score 0/1/2)
showed a significant association with reduced DFS
(p=0.01). Stronger Trop-2 immunostaining showed a
trend towards significance for overall and progression-
free survival (Figure 1B and 1C, p=0.06 and p=0.05,
respectively). Trop-2 protein overexpression and advanced
FIGO stage were identified as independent predictive fac-
tors for poor DFS (p=0.04 and p<0.001, respectively,
Table 2) in multivariate analyses.
Discussion
In this study, we used tissue microarrays to demonstrate
that Trop-2 protein overexpression is significantly asso-
ciated with higher tumor grade as well as cervical involve-
ment and serves as an independent prognostic factor for
DFS in EEC. A trend towards significance between Trop-2
expression and OS and PFS was exhibited and would
likely have been achieved for OS with larger sample size
or longer median follow-up, as greater time is required
to demonstrate differences in OS compared to other end-
points [34]. Nevertheless, DFS has been shown to be
highly correlated with OS and is increasingly received as
an acceptable endpoint [35]. These findings are consist-
ent with previous reports that suggest that Trop-2 over-
expression identifies biologically aggressive phenotypes
and poorly differentiated disease [24,28-31]. Though
Trop-2 has been shown to be an excellent candidate anti-
gen for targeted immunotherapy in multiple gynecologic
malignancies including EEC [24], uterine papillary serous
carcinomas [22], chemotherapy-resistant [23] and sensi-
tive ovarian carcinomas [32], and cervical carcinomas
[25], this is the first proof that Trop-2 overexpression
can also prognosticate patient outcome in EEC.
The role of Trop-2 in cancer pathogenesis remains
incompletely elucidated. In accordance with its original
identification in trophoblasts, which possess the capacity
to invade uterine decidua during the process of placental
implantation, Trop-2 may analogously confer to cancer
cells the capacity for proliferation and invasion [36,37].
Wang et al. (2008) [38] demonstrated the role of Trop-2
in anchorage-independent growth and the oncogenic po-
tential of Trop-2 in colon cancer cells using both in vitro
and in vivo models. Trop-2 has been shown to directly
mediate tumor-associated calcium-mediated signal cas-
cades [39] and activation of ERK 1/2-MAPK pathways
[36], both of which govern cell cycle progression [40,41]
and may protect cancer cells from apoptosis [42]. A
Table 1 Clinical and pathologic characteristics of 118 endometrioid endometrial cancer patients and their association
to Trop-2 protein expression
Trop-2 protein expression
Variable n Score≤1 n (%) Score=2 n (%) Score=3 n(%) p value*
Age at diagnosis
<65 51 22 (43.1) 17 (33.3) 12 (23.5)
0.89
≥65 67 28 (41.8) 26 (38.8) 13 (19.4)
FIGO stage(2009 criteria)
I-II 86 37 (43) 33 (38.4) 16 (18.6)
0.56
III-IV 22 8 (36.4) 6 (27.3) 8 (36.4)
Unknown 10 5 (50) 4 (40) 1 (10)
WHO grading
Grade 1 34 21 (61.8) 11 (32.4) 2 (5.9)
0.024
Grade 2-3 84 29 (34.5) 32 (38.1) 23 (27.4)
Myometrial invasion
M0+M1 55 26 (47.3) 22 (40) 7 (12.7)
0.08
M2 63 24 (38.1) 21 (33.3) 18 (28.6)
Lymph node status
Negative 79 35 (44.3) 28 (35.4) 16 (20.3)
0.69
Positive 15 5 (33.3) 5 (33.3) 5 (33.3)
Unknown 24 10 (41.7) 10 (41.7) 4 (16.7)
Cervical involvement
Absent 83 37 (44.6) 33 (39.8) 13 (15.7)
Glandular involvement 16 10 (62.5) 4 (25) 2 (12.5) <0.01$
Stromal involvement 18 3 (16.7) 6 (33.3) 9 (50)
Unknown 1 0 (0) 0 (0) 1 (100)
Adnexal involvement
Negative 108 45 (41.7) 42 (38.9) 21 (19.4) 0.97
Positive 9 5 (55.6) 0 (0) 4 (44.4)
Unknown 1 0 (0) 1 (100) 0 (0)
Peritoneal cytology
Negative 100 40 (40) 37 (37) 23 (23)
0.44
Positive 8 4 (50) 2 (25) 2 (25)
Unknown 10 6 (60) 4 (40) 0 (0)
Lymphovascular invasion
Absent 48 22 (45.8) 20 (41.7) 6 (12.5)
0.13
Present 56 21 (37.5) 20 (35.7) 15 (26.8)
Unknown 14 7 (50) 3 (21.4) 4 (28.6)
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Table 1 Clinical and pathologic characteristics of 118 endometrioid endometrial cancer patients and their association
to Trop-2 protein expression (Continued)
Adjuvant Treatment
None 57 31 (54.4) 20 (35.1) 6 (10.5)
Radiotherapy 36 12 (33.3) 13 (36.1) 11 (30.6)
Chemotherapy 8 3 (37.5) 1 (12.5) 4 (50.0) 0.094$
Radiotherapy+Chemotherapy 9 2 (22.2) 5 (55.6) 2 (22.2)
Unknown 8 5 (62.5) 2 (25.0) 1 (12.5)
Parity
Nulliparity 22 10 (45.5) 7 (31.8) 5 (22.7)
0.72
Multiparity 88 34 (38.6) 35 (39.8) 19 (21.6)
Unknown 8 6 (75) 1 (12.5) 1 (12.5)
Body Mass Index
<25 36 12 (33.3) 14 (38.9) 10 (27.8)
0.58
≥25 64 27 (42.2) 24 (37.5) 13 (20.3)
Unknown 18 11 (61.1) 5 (27.8) 2 (11.1)
Hypertension
Negative 48 18 (37.5) 18 (37.5) 12 (25)
0.26
Positive 63 27 (42.9) 24 (38.1) 12 (19)
Unknown 7 5 (71.4) 1 (14.3) 1 (14.3)
Diabetes
Negative 96 38 (39.6) 39 (40.6) 19 (19.8)
0.95
Positive 15 8 (53.3) 2 (13.3) 5 (33.3)
Unknown 7 4 (57.1) 2 (28.6) 1 (14.3)
Menopausal Status
Premenopausal 18 7 (38.9) 5 (27.8) 6 (33.3)
0.33
Postmenopausal 94 39 (41.5) 37 (39.4) 18 (19.1)
Unknown 6 4 (66.7) 1 (16.7) 1 (16.7)
Smoking
Negative 82 29 (35.4) 35 (42.7) 18 (22)
0.91
Positive 20 9 (45) 6 (30) 5 (25)
Unknown 16 12 (75) 2 (12.5) 2 (12.5)
* Exact Wilcoxon-Mann–Whitney test.
$ Non-parametric ANOVA.
Unknown values were considered as missing and therefore excluded from the statistical analysis.
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nate (PIP2) binding sequence that overlaps with a protein
kinase C phosphorylation sites within the cytoplasmic
tail suggests a specific role in signal transduction [43,44].
Recently, Trerotola et al. [45] demonstrated that Trop-2
upregulation is necessary and sufficient to promote cellgrowth in different cancer cell types and that its somatic
knockdown is able to extinguish tumor cell growth. The
Trop-2 transcription control network, including factors
activating Trop-2 expression or downstream growth-
stimulatory pathways has been recently reported [46].
Interestingly, Trop-2-cyclin D1 chimeric mRNAs have
Table 2 Univariate and multivariate analyses of OS, DFS and PFS in relation to clinical parameters and Trop-2 protein
expression
OS DFS PFS
Variables N=97 HR 95%CI p N=93 HR 95%CI p N=97 HR 95%CI p
Univariate analysis
Age
<65 vs ≥65 103 1.23 0.46-3.28 0.68 93 1.06 0.41-2.75 0.90 102 1.37 0.49-3.79 0.54
FIGO stage
III-IV vs I-II 97 17.05 5.47-53.17 <0.01 93 5.88 2.25-15.34 <0.01 96 16.73 5.28-53.03 <0.01
Tumor grade
G1 vs G2-G3 103 0.001 -* 0.68 99 0.155 0.02-1.18 0.07 102 0.001 -* 0.69
Lymph node involvement
positive vs negative 87 10.17 3.22-32.11 <0.01 85 6.05 2.09-17.51 <0.01 86 14.07 4.08-48.49 <0.01
Trop-2 IHC
score=3 vs score 0/1/2 103 2.60 0.94-7.19 0.06 99 3.36 1.26-8.92 0.01 102 2.80 0.99-7.87 0.05
Multivariate analysis
Trop-2 IHC 97 93 97
score=3 vs score 0/1/2 1.83 0.65-5.18 0.25 2.82 1.05-7.58 0.04 1.76 0.63-4.88 0.28
FIGO stage 97 93 97
III-IV vs I-II 15.94 5.08-50.04 <0.001 5.36 2.04-14.08 <0.001 16.73 5.31-52.73 <0.001
*Because of the small number of events (deaths and progressions) in the G1 EEC category, the confidence interval was not reliable.
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lend enhanced stability to cyclin D1, resulting in cellular
immortalization [47] and possibly prevention of anoikis
[48]. Of note, Trop-2 expression appears to discriminate
populations with stem-like activity [49], which may be
important for initiation and perpetuation of cancers
[50,51]. A different role of Trop-2 in cancer growth has
been recently reported by Lin et al. [52] in lung carcin-
oma, where Trop-2 is epigenetically downregulated and
affected by LOH, resulting in cancer progression via acti-
vation of IGF-1R signalling.
In this report, we provide immunostaining results indi-
cative of protein expression. Immunohistochemistry is
widely accepted as an adjunct technique to routine
histologic analysis to offer additional diagnostic and
prognostic information [53]. We did not evaluate Trop-2
at the mRNA level since transcript copy number and
protein expression are poorly concordant for this anti-
gen [32]. This phenomenon is not uncommon; genomic
analyses at best are believed to capture only 40% of
proteomic variations due to post-transcriptional regula-
tory mechanisms in mammalian cells [54].
Generally accepted prognostic factors for endometrial
carcinoma are nodal involvement/stage, grade, and
histologic subtype [55]. As anticipated, in this cohort
Trop-2 overexpression correlated with grade and pro-
pensity for cervical involvement. Tumor location within
the uterus has potential clinical relevance, since thelymphatic drainage of the cervix differs from that of the
fundus in that it is much more rich and tends to involve
the pelvic as opposed to the para-aortic nodes [56].
Many recent attempts to discover novel prognostic
factors for endometrial cancer have been discouraging.
Koyuncuoglu et al. (2012) [57] described the loss of
e-cadherin expression in association with advanced stage
and poor differentiation in both EEC and non-EEC, but
failed to demonstrate statistical significance between e-
cadherin levels and survival using multivariate analyses.
Similarly, while Mhawech-Fauceglia et al. (2012) [58]
noted a high percentage of uterine papillary serous and
EEC cases with expression of the tight junction protein
claudin-7 and the cytoskeletal protein moesin, no asso-
ciation existed between these proteins and overall or
disease-free survival.
Conclusions
In summary, we provide the first demonstration that
Trop-2 overexpression prognosticates poor disease-free
survival in EEC. This study corroborates previous reports
on the importance of Trop-2 expression in human
tumors to stratify biologically aggressive disease variants.
Importantly, because Trop-2 overexpression may repre-
sent an independent prognostic factor for earlier cancer
recurrence, its determination in EEC tissue samples may
be clinically useful in the attempt to identify patients at






Figure 1 Univariate survival analysis according to Trop-2 immunostaining on 103 EEC patients. Kaplan-Meier survival curves displaying
that stronger Trop-2 immunostaining (IHC score 3 versus IHC score 0/1/2) exhibits a significant association with reduced DFS (Figure 1A, p=0.01),
while it shows a trend towards significance for overall and progression-free survival (Figure 1B and 1C, p=0.06 and p=0.05, respectively) on a
cohort of 103 EEC patients.
Bignotti et al. BMC Clinical Pathology 2012, 12:22 Page 7 of 9
http://www.biomedcentral.com/1472-6890/12/22to optimize follow up and adjuvant treatments. These
data, however, should be confirmed in additional studies
on larger patient cohorts before routine Trop-2 IHC
evaluation may be applied in the clinical setting.
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